Biologicznie aktywne pochodne 1,8-naftyrydyny

• Autorzy: Suryło, P. , Kowalski, P. , Hołda, M.

Warianty tytułu

EN

Biologically active 1,8-naphthyridine derivatives

• Języki publikacji: PL

Abstrakty

EN

This review attempts to briefly summarise the recent developments in the synthesis and application of 1,8-naphthyridine derivatives as biological active compounds. A large number of these compounds still evolves interest of chemists and pharmacologists. From among of one thousand papers, which appeared within the last fifteen years, most described applications of 1,8-naphthyridine derivatives as biologicaly active compounds. Nalidixic acid (1) was the first 1,8-naphthyridine derivative approved as the drug with antibacterial activity. There are many routes to the synthesis of nalidixic acid. The main routes are presented in the Schemes 1, 4, and 6. This compound was the first from the quinolone's family applied as the chemotherapeutic drug. Modification of the structure of nalidixic acid brought the discovery of a new group of most potent antibacterial compounds called fluoroquinolones. Enoxacine (16), esafloxacine (21), tosulfoxacine (22), trovafloxacine (23) and alatrofloxacine (24) are the examples of 1,8-naphthyridine derivatives belonging to that group. General reaction scheme of synthesis of 16 and 21 is similar to synthesis of nalidixic acid, while synthesis of the compounds 22, 23, and 24 presented in Scheme 8 is quite different. Moreover, many other 1,8-naphthyridine derivatives 31-40 have been intensively studied as antibacterial agents in vitro, but none of them has been applied as a drug. A number of 2- and 7-substituted 1,8-naphthyridines 41 showed some antimalarial activity in vivo, while the compounds of general structure 42 were found inactive. 2(4)-Piperazinyl-1,8-naphthyridines (45) have been pharmacologically investigated for their antyhipertensive activity. 1,8-Naphthyridines 46, bearing a phenyl group in position 2, were found to be selective antagonists for the A1 adenosine receptor subtype. A series of 1,8-naphthyridines 47-49 exhibited appreciable diuretic and antikaliuretic activity in rats. In search for potential anticancer compounds study such as SAR (structure activity relationship) and QSAR (quantity structure activity relationship) have been used. As the result of the research the structure of the compounds 50 has established as the most potent inhibitor of tubulin polymerization. The nitrobenzo-1,8-naphthyridines (52)constitute a group of potential interest for the design of new cytotoxins. Moreover, 1,8-naphthyridine derivatives have been found to be active as inhibitors of platelet aggregation agents 53-54 ; antiviral 56-57 and antialergic agents 62. These derivatives possess bronchodilating 64, antiflammatory and sedative properties 67.

Słowa kluczowe

PL

pochodne 1,8-naftyrydyny; kwas nalidiksowy; lecznictwo; farmaceutyk

EN

nalidixic acid; 1,8-naphthyridine derivatives; pharmacology

• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2003
• Tom: [Z] 57, 3-4
• Strony: 247--266
• Opis fizyczny: Bibliogr. 59 poz., schem.

Twórcy

autor

Suryło, P.

• Politechnika Krakowska, Instytut Chemii i Technologii Organicznej ul. Warszawska 24 31-155 Kraków

autor

Kowalski, P.

• Politechnika Krakowska, Instytut Chemii i Technologii Organicznej ul. Warszawska 24 31-155 Kraków,

autor

Hołda, M.

• Politechnika Krakowska, Instytut Chemii i Technologii Organicznej ul. Warszawska 24 31-155 Kraków

Bibliografia

• [1] M. Woźniak, H.C. van der Plas, Adv. Heterocyclic Chem., 2000,77, 285.
• [2] V.P. Litvinov, S.V. Roman, V.D. Dyachenko, Usp. Khim., 2000, 69,219.
• [3] H. Miao, V. Cecchetti, O. Tabarrini, A. Fravolini, J. Heterocyclic Chem., 2000,37, 297.
• [4] Centers for Disease Control and Prevention, Facts and Anthrax, September 2001, www.cdc.gov.
• [5] H.P. Lambert, F.W. O’Grady, Antybiotyki i chemioterapia, Wydawnictwo Medyczne, Warszawa 1994.
• [6] T. Tkaczyński, D. Tkaczyńska, Synteza i technologia chemiczna leków, PZWL Warszawa 1984.
• [7] Wybrane zagadnienia z metod poszukiwania i otrzymywania środków leczniczych, red. K. Kieć-Kononowicz, Wydawnictwo UJ, Kraków 2000.
• [8] C. Lesker, E. Froehlick, M. Grutt, J. Bailey, R. Brundage, J. Med. Pharm. Chem., 1962, 5, 1063.
• [9] K.D. Demidova, V.V. Kazakova, T.I. Kudryashova, M.B. Lis, B.A. Morozov, A.G. Pechenkin, O.E. Pylacva, E.A. Rudzit, G.Kh. Khisamutdinov, KE. Chistyakov, Med. Prom. SSSR, 1967,20(6), 18; Chem. Abstr. 1967, 66, 2494u.
• [10] R. Albrecht, Progress in Drug Research, 1977,21, 9.
• [11] Z Meszaros, I. Hermecz, Tetrahedron Lett., 1975, 1019.
• [12] Y.I. Wada, N.S. Watanabe, Patent japoński, 72 25 349 (1972); Chem. Abstr., 1972,77, 88322
• [13] Y. Morita, K. Wagatsuma, Patent japoński, 74 109 383 (1974); Chem. Abstr., 1975, 83, 9796.
• [14] J.K. Podlewski, A. Chwalibogowska-Podlewska, Leki współczesnej terapii - suplement do wyd. IX i X, Fundacja Buchnera, Warszawa 1992.
• [15] J. Matsumoto, T. Miyamoto, A. Minamida, Y. Nishimura, H. Egawa, H. Nishimura, J. Med. Chem., 1984, 27, 292.
• [16] H. Egawa, T. Miyamoto, A. Minamida, Y. Nishimura, H. Okada, H. Uno, J. Matsumoto, J. Med. Chem., 1984, 27, 1543.
• [17] The Merck Index, wyd. 12, Merck and Co., Inc., Whitehouse Station, N.J., USA 1996
• [18] T. Norris, Patent USA, 6 114 531 (2000).
• [19] B. Singh, G.Y., Lesher, J. Heterocyclic Chem., 1983, 20,491.
• [20] A.A. Santilli, A.C. Scotese, J.A. Yurchenco, J. Med. Chem., 1975,18, 1038.
• [21] K. Mogilaiah, D. Srinivasa Chowdary, R. Babu Rao, Ind. J. Heterocyclic Chem., 2000,9, 311.
• [22] N. Suzuki, Y. Tanaka, R. Dohmori, Chem. Pharm. Bull., 1980,28, 235.
• [23] A.A. Santilli, A.C. Scotese, R.F. Bauer, S.C. Bell, J. Med. Chem., 1987,30,2270.
• [24] N. Suzuki, M. Kato, R. Dohmori, Yakugaku Zasshi, 1979,99,155; Chem. Abstr., 1979,91,56865g.
• [25] R.A. Mekheimer, Synthesis, 2001, 103.
• [26] S. Goswami, B.K. Ghosh, R. Mukherjee, A.K. Adak, A.K. Mahaparta, J. Heterocyclic Chem., 2001,38, 173.
• [27] T.R. Sweeney, R.E. Strube, Burger's Medicinal Chemistry, Ed. 4, M.E. Wolff, Ed., Interscience Inc., New York, N.Y., 1979.
• [28] G.B. Barlin, Weng-Lai Tan, Aust. J. Chem., 1986,37,1065.
• [29] F.I. Carroll, B.D. Berrang, C.P. Linn, J. Heterocyclic Chem., 1981,18, 941.
• [30] C.S. Rooney, H.W.R. Williams, K.B. Wasson, Patent USA, 3 993 656; Chem. Abstr., 1976, 86, 106555.
• [31] H.W.R. Williams, C.S. Rooney, Patent USA, 4 031 103; Chem. Abstr., 1977, 87, 117836.
• [32] S. Carboni, A. De Settimo, P.L. Ferrarini, G. Primofiore, O. Livi, V. Menichetti, M. Del Tacca, E. Martinotti, C. Bemardini, A. Bertelli, Eur. J. Med. Chem. - Chim. Ther., 1982, 17, 159, Chem. Abstr. 1982,97, 6I92p.
• [33] P.L. Ferrarini, C. Mori, G. Primofiore, J. Heterocyclic Chem., 1986, 23, 501.
• [34] P.L. Ferrarini, C. Mori, M. Badawneh, V. Calderone, L. Calzolari, T. LolTredo, F., Martinotti, G. Saccomanni, Eur. J. Med. Chem., 1998,33, 383.
• [35] P.L. Ferrarini, C. Mori, V. Calderone, L. Calzolari, P. Nieri, G. Saccomanni, E. Martinotti, Eur. J. Med. Chem., 1999,34, 505.
• [36] P.L. Ferrarini, C. Mori, C. Manera, A. Martinelli, F. Mori, G. Saccomanni, P.L. Barili, L. Betti, G. Giannaccini, L. Trincavelli, A. Lucacchini, J. Med Chem., 2000, 43, 2814.
• [37] EM. Hawes, D.J. Gorecki, J. Med. Chem., 1973,16, 849.
• [38] D.K.J. Gorecki, E.M. Hawes, J. Med. Chem., 1977,20,124.
• [39] E.M. Hawes, D.K.J. Gorecki, R.G. Gedir, J. Med. Chem., 1977,20, 838.
• [40] S. Zhang, J. Feng, S. Kuo, A. Brossi, E. Hamel, A. Tropsha, K. Lee, J. Med. Chem., 2000,43, 167.
• [41] A. Monge, S. Norro, F.J. Martinez-Crespo, A. Lopez de Cerain, E. Hamilton, A.J. Barker, Eur. J. Med. Chem., 1994,29,441.
• [42] I. Tonetti, D. Bertini, Farmaco Ed. Sei., 1976, 31, 175.
• [43] P.L. Ferrarini, C. Mori, M. Miceli, F. Franconi, Eur. J. Med. Chem., 1994,29, 735.
• [44] W.A. Bolhofer, J.M. Hoffman, J. Med. Chem., 1972, 22, 301.
• [45] A. Bechand, S. Levesque, N. Nguyen-Ba, A. Siddiqui, Patent, WO 0050424 (2000).
• [46] V. Vaillancourt, Patent, WO 0170742 (2001).
• [47] S. Carboni, A. Da Settimo, D. Bertini, P.L. Ferrarini, O. Livi, I. Tonetti, Farmaco Ed. Sei., 1975,30, 185.
• [48] S. Carboni, A. Da Settimo, D. Bertini, P.L. Ferrarini, O. Livi, I. Tonetti, Farmaco Ed. Sei., 1975,30, 237.
• [49] D.R. Buckle, B. Christian, B. C. Cantello, H. Smith, Patent brytyjski, I 453 863 (1976).
• [50] B.R. Buckle, B.C. Cantello, H. Smith, J. Med. Chem., 1975,18, 726.
• [51] D.R. Buckle, H. Smith, B.C. Cantello, Patent brytyjski, 1 490 998 (1977); Chem. Abstr., 1978,88, 190795a.
• [52] T. Kuroda, F. Suzuki, J. Heterocyclic Chem., 1991, 28, 2029.
• [53] F. Suzuki, T. Kuroda, T. Kawakita, H. Manabe, S. Kitamura, K. Ohmori, M. Ichimura, H. Kase, S. Ichikawa, J. Med. Chem., 1992,35,4866.
• [54] M. Di Braccio, G. Roma, A. Balbi, A. Sottofattori, M. Carazzone, Farmaco, 1989,44, 865.
• [55] M. Di Braccio, G. Roma, M. Ghia, F. Mattioli, Farmaco, 1994,49, 25.
• [56] M. Di Braccio, G. Roma, G.C. Rossi, M. Ghia, F. Mattioli, Farmaco, 1997,52, 49.
• [57] G. Roma, M. Di Braccio, G. Grossi, F. Mattioli, M. Ghia, Eur. J. Med. Chem., 2000, 35, 1021.
• [58] Informacja o lekach firmy Pfizer; www.pfizer.com.
• [59] Pharmindex 01 — Kompendium Leków, Wydawnictwo MediMedia International sp. z o.o., Warszawa 2000.